The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Fresenius Kabi; MSD; Novartis; Roche
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); BB Biotech Ventures (Inst); BeiGene (Inst); BioAlliance Pharma (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cephalon (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); H3 Biomedicine (Inst); Incyte (Inst); Innate Pharma (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Merus (Inst); Millennium (Inst); Molecular Partners (Inst); Nanobiotix (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Novartis (Inst); Octimet (Inst); Oncoethix (Inst); OncoMed (Inst); Oncopeptides (Inst); Onyx (Inst); Orion (Inst); Oryzon Genomics (Inst); Ose Pharma (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); Pierre Fabre (Inst); Pierre Fabre (Inst); Plexxikon (Inst); RigonTEC (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi/Aventis (Inst); SERVIER (Inst); Sierra Oncology (Inst); Sotio (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tioma Therapeutics (Inst); Wyeth (Inst); Xencor (Inst); Y's Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2
Travel, Accommodations, Expenses - AstraZeneca; MSD
Other Relationship - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
 
Stéphane Champiat
No Relationships to Disclose
 
Philippe A. Cassier
Honoraria - Amgen; AstraZeneca; Merck Serono; Novartis; Roche/Genentech
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Netris Pharma; Novartis; Roche
 
Nuria Kotecki
No Relationships to Disclose
 
Iphigenie Korakis
No Relationships to Disclose
 
Armelle Vinceneux
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Christiane Jungels
Travel, Accommodations, Expenses - Ipsen; PharmaMar
 
Jon Blatchford
Consulting or Advisory Role - Boehringer Ingelheim
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Mabrouk M. Elgadi
Employment - Boehringer Ingelheim
 
Nicole Clarke
Employment - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Claudia Fromond
Employment - OSE Immunotherapeutics
Stock and Other Ownership Interests - OSE Immunotherapeutics
 
Nicolas Poirier
Employment - OSE Immunotherapeutics
Leadership - OSE Immunotherapeutics
Stock and Other Ownership Interests - OSE Immunotherapeutics
Patents, Royalties, Other Intellectual Property - I'm author of several patents filed by OSE Immunotherapeutics in the domain of immuno-oncology and immunotherapies
 
Berangere Vasseur
Employment - OSE Immunotherapeutics
Stock and Other Ownership Interests - OSE Immunotherapeutics
 
Aurelien Marabelle
Stock and Other Ownership Interests - Centessa Pharmaceuticals; Centessa Pharmaceuticals (Inst); HiFiBiO Therapeutics; PEGASCY; PEGASCY (Inst); Shattuck Labs
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Oncovir
Consulting or Advisory Role - AstraZeneca; Centessa Pharmaceuticals; Eisai; HiFiBiO Therapeutics; ImCheck therapeutics; Innate Pharma; Lytix Biopharma; MedinCell; MSD; OSE Immunotherapeutics; Pierre Fabre; Redx Pharma; Roche; SERVIER; Sotio
Speakers' Bureau - BMS
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - AstraZeneca; MSD
 
Jean-Pierre Delord
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis; Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); MSD Oncology (Inst); Transgene (Inst)